EU/3/18/2056: Orphan designation for the treatment of idiopathic pulmonary fibrosis

(S)-(−)-3-(4-aminophenyl)-2-methoxypropanoic acid


On 24 August 2018, orphan designation (EU/3/18/2056) was granted by the European Commission to Nogra Pharma Limited, Ireland, for (S)-(−)-3-(4-aminophenyl)-2-methoxypropanoic acid (also known as GED-0507-34-Levo) for the treatment of idiopathic pulmonary fibrosis.

Key facts

Active substance
(S)-(−)-3-(4-aminophenyl)-2-methoxypropanoic acid
Intended use
Treatment of idiopathic pulmonary fibrosis
Orphan designation status
EU designation number
Date of designation

Nogra Pharma Limited
33 Sir John Rogerson's Quay
Dublin 2
Tel. +353 87 6203961

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating